Sung Young-sook, chairwoman of Hanmi Pharmaceutical Group, said in her New Year's message posted on the company intranet on the 2nd, "Let us break free from the old shell and reorganize ourselves to advance boldly on a global scale."
Chairwoman Sung expressed gratitude to the employees who achieved many results last year, saying, "Let us take strong steps toward a new future with creative innovation and a spirit of challenge, like the blue snake, which symbolizes wisdom, determination, and flexibility."
Chairwoman Sung mentioned last year's achievements in domestic and overseas business and research and development (R&D). She reported that the composite new drug for dyslipidemia, "Rosuzet," ranked first in domestic prescriptions outside of hospitals for the seventh consecutive year. In the overseas business sector, she noted exports of finished goods to the Middle East, and in the R&D sector, she highlighted the development of the obesity treatment agent, epeglinanatide, based on glucagon-like peptide-1 (GLP-1). She assessed last year's achievements, stating, "Despite difficulties, Hanmi Pharmaceutical clearly showed the direction it needs to go."
Chairwoman Sung noted, "The year 2025 is an important year for Hanmi Group to prepare for a new leap," and said, "Like a wise snake shedding its skin and being reborn to grow even larger, Hanmi Group should shed its old shell and move forward to soar globally." She added, "The dedication and passion of all Hanmi Group employees are Hanmi's greatest asset and the driving force opening our future," promising, "We will spare no support to ensure that Hanmi's challenges and dedication bear fruit."